Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessio Stefani

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2025
Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapyFederico Monaca, Igor Gomez-Randulfe, Ana Sofia Parreira, et al.
Frontiers in Oncology|September 12, 2025
Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumabSerena Eccher, Marco Sposito, Ilaria Trestini, et al.
Therapeutic Advances in Medical Oncology|November 12, 2025
PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevanceSara Pilotto, Lorenzo Belluomini, Federico Monaca, et al.
The Oncologist|February 20, 2024
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb TrialEmilio Bria, Floriana Morgillo, Marina Chiara Garassino, et al.
Clinical Lung Cancer|July 30, 2025
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study ResultsFloriana Morgillo, Ester Del Signore, Emilio Bria, et al.
Cancer Immunology, Immunotherapy : CII|September 5, 2023
Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)Emanuele Vita, Alessio Stefani, Geny Piro, et al.
JCO Precision Oncology|October 7, 2024
Impact of Comprehensive Genome Profiling on the Management of Advanced Non-Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 ProgramAntonio Vitale, Luca Mastrantoni, Jacopo Russo, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2025
Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapyFederico Monaca, Igor Gomez-Randulfe, Ana Sofia Parreira, et al.
Frontiers in Oncology|September 12, 2025
Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumabSerena Eccher, Marco Sposito, Ilaria Trestini, et al.
Therapeutic Advances in Medical Oncology|November 12, 2025
PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevanceSara Pilotto, Lorenzo Belluomini, Federico Monaca, et al.
The Oncologist|February 20, 2024
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb TrialEmilio Bria, Floriana Morgillo, Marina Chiara Garassino, et al.
Clinical Lung Cancer|July 30, 2025
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study ResultsFloriana Morgillo, Ester Del Signore, Emilio Bria, et al.
Cancer Immunology, Immunotherapy : CII|September 5, 2023
Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)Emanuele Vita, Alessio Stefani, Geny Piro, et al.
JCO Precision Oncology|October 7, 2024
Impact of Comprehensive Genome Profiling on the Management of Advanced Non-Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 ProgramAntonio Vitale, Luca Mastrantoni, Jacopo Russo, et al.
Pageof 4